Published in final edited form as:

Trends Cancer. 2018 September ; 4(9): 643–654. doi:10.1016/j.trecan.2018.07.004.

Improving Cancer Detection and Treatment with Liquid Biopsies and ptDNA

Michael D. Kessler^{1,3}, Nisha R. Pawar^{2,4}, Stuart S Martin^{4,5}, Toni M. Antalis^{4,5}, and Timothy D. O'Connor^{1,2,3,4}

¹Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore MD 21201

²Department of Medicine, University of Maryland School of Medicine, Baltimore MD 21201

³Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore MD 21201

⁴University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore MD 21201

⁵Department of Physiology, University of Maryland School of Medicine, Baltimore MD 21201

Abstract

Liquid biopsy, or the capacity to non-invasively isolate and analyze plasma tumor DNA (ptDNA) using blood samples, represents an important tool for modern oncology that enables increasingly safe, personalized and robust cancer diagnosis and treatment. Here, we review advances in the development and implementation of liquid biopsy approaches, and we focus on the capacity of liquid biopsy to non-invasively detect oncological disease and enhance early detection strategies. In addition to noting the distinctions between mutation targeted and mutation agnostic approaches, we discuss the potential for genomic analysis and longitudinal testing to identify somatic lesions early, and to guide intervention at more manageable disease stages.

Liquid biopsy of ptDNA for the treatment of cancer

Liquid biopsy, or the analysis of a liquid specimen that is often obtained in a noninvasive or minimally invasive manner, has emerged as a potentially useful way to personalize and improve the detection and treatment of cancer. Cell-free DNA (cfDNA), which is released from cells by apoptosis, necrosis, or active secretion, is often sampled by liquid biopsy from body fluids such as blood 1-5, urine 5-8, saliva 5,9, and cerebrospinal fluid 5,10,11,12-15 (Figure 1). There has been considerable focus on the use of blood for the identification of potential tumor biomarkers, including circulating tumor cells 4,16, extracellular tumor-derived vesicles 16,17, and the cfDNA that is released from cancer cells 5,15,18,19. Since

Corresponding author: Michael D. Kessler, Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore MD 21201. Phone: 516-967-1732. michael.kessler@som.umaryland.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

the term cfDNA refers to cell-free DNA found in a multitude of body fluids, and most liquid biopsies aim to isolate cfDNA specifically from blood plasma, the acronym pDNA would appear to be a more specific term for the cfDNA detected in blood plasma (Figure 1). Genetic and epigenetic analyses suggest that the majority of pDNA in both healthy and diseased individuals originates from hematopoietic cells (in particular from white blood cells), and that cancer patients have elevated levels of pDNA deriving from tumor tissue 5,20-22. In individuals with cancer, the subset of pDNA that derives from tumor cells is often referred to as plasma tumor DNA (ptDNA) 23 (Figure 1). While circulating tumor DNA, or ctDNA, is another frequent term used for tumor-derived pDNA 24-28, we prefer the more specific term ptDNA, since ctDNA can also refer to the tumor-derived cfDNA that is found in any body fluid (Figure 1).

Due to its short half-life and tendency to carry unique and cancer-associated mutations, ptDNA is an attractive tumor biomarker that facilitates the highly specific assessment of tumor dynamics, disease burden, and genomic alterations. 27,29. This specificity is particularly important given the current dearth of highly specific tumor biomarkers 27,30,31. However, the very low concentration of ptDNA compared with background normal DNA, especially during early stages of cancer, presents a technical challenge to the use of ptDNA as a clinical tool. Nonetheless, increasingly sensitive and scalable methods for the detection of ptDNA are emerging. Here we review the use of ptDNA for detecting tumor burden, assessing relapse risk, dynamically monitoring response to treatment, and informing personalized therapy. We highlight the challenges of using ptDNA to detect early stage cancer and discuss the potential of *in silico* analytical approaches and longitudinal surveillance to improve the use of ptDNA.

Using ptDNA to assess relapse risk and monitor tumor dynamics in advanced cancers

PCR approaches showed that patients with advanced colorectal cancers (CRCs) have mutations in the adenomatous polyposis coli (*APC*) gene in 8% of total APC blood DNA fragments 32. In ovarian cancer mouse models, ptDNA strongly correlates with tumor weight/burden and can potentially be used as a marker of response to therapy 33. Mutant ptDNA could also be used to track tumor dynamics in response to treatment. In CRC patients who had complete surgical resection, the levels of mutant ptDNA dropped markedly, whereas patients who had partial resection showed only moderate decreases 29. Remarkably, patients with detectable ptDNA levels at their first follow-up visit relapsed (15/16), whereas patients with no detectable ptDNA did not relapse (4/4) 29. Similarly, ptDNA decreased in patients receiving chemotherapy (3/11) and rose immediately after discontinuation of chemotherapy (6/11) 29. Ultimately, ptDNA can potentially be used to successfully identify residual disease that is undetectable by imaging after local resection and could track patient tumor responses to treatment.

Digital droplet PCR (ddPCR) increased analytical sensitivity and enabled the detection of 1 mutant DNA molecule per 100,000 normal DNA molecules 34. This suggested that ptDNA was a far more sensitive biomarker than circulating tumor cells, and that ptDNA can more

accurately capture a tumor's mutational profile 16. Using targeted amplification followed by next-generation sequencing, a novel approach called tagged amplicon deep sequencing (TAm-Seq), enabled entire genes of interest to be sequenced and scrutinized for genetic alterations without *a priori* knowledge of a tumor's driver mutations 24. This also allowed for the identification of mutations not found in primary tumors and potentially underpinning acquired resistance. While this method has been clinically limited by high read depth requirements and an analytical sensitivity requiring allele frequencies of at least 2%, it has facilitated the use of numerous mutations in parallel to accurately monitor disease dynamics 24. The use of multiple mutations in parallel has also been used by others 25, and can greatly reduce the likelihood of false negatives due to sampling noise.

Further advances were made by using both digital PCR, which requires targeting personalized mutations from patient-derived tumor specimens, and the mutation-nonspecific TAm-Seq platform to show that metastatic breast cancer can be effectively tracked with ptDNA 25. This study showed that ptDNA could signal progressive disease an average of five months earlier than imaging in a majority of patients 25. Others also showed that a targeted approach with digital PCR could be used to detect the acquisition of gene amplifications in metastatic breast cancers 35. Focusing on *HER2* gene amplifications, which can be acquired or lost over the course of disease and can be successfully targeted by therapeutic antibodies, this study highlighted the potential of noninvasive assays to guide hormone-based treatments in an increasingly personalized manner 35. Exome-focused analysis of ptDNA was used to complement traditional invasive approaches in identifying drug resistance-mediating mutations in advanced cancers 26 (Figure 3). This study included two cases for which blood samples were collected along with traditional biopsies, which allowed full representation of the tumor genomes in the blood plasma 26 (Figure 3).

Whereas nearly all early studies on the use of ptDNA in cancer treatment had dealt with a single tumor type, Bettegowda et al. 27 set out to examine over 15 cancer types from 640 patients. Since certain tumor samples can be difficult to obtain due to clinical and/or logistic limitations 36, and others are obtained through needle-based biopsies that provide insufficient material for genetic analysis 37, understanding the potential of liquid biopsy across tumor type is paramount. The authors focused on estimating the percentages of patients with detectable mutant DNA across different tumor types, how the amounts of detected mutant DNA differed between and within tumor types, how this detection capacity varied based on disease advancement, and how mutant DNA amount varied by disease stage. The somatic mutations identified in each of the tumors of 410 patients with advanced cancers were found to be highly specific for cancer cells, and a specificity of 99.2% for *KRAS* mutations was identified in a distinct cohort of 206 metastatic CRC patients. The diagnostic sensitivity in this context was also impressive (>87%,) and was higher than most conventional biomarkers 27,30. Furthermore, high levels of ptDNA prognosticated a poor two-year survival, with implications for disease tracking and clinical planning, and there was significant variation across and within tumor type in the number of mutant molecules per 5ml of plasma. While some tumor types, such as gliomas, showed both low mutant molecule amounts and a low percentage of patients with detectable ptDNA levels, numerous other tumors showed moderate to high levels of ptDNA in spite of a low number of patients with these tumors having detectable ptDNA. Some of this variation in detection is likely due to

differences in the average disease stage at the time of detection across tumor type, as well as differences in the amounts of tumor DNA released into the bloodstream by different tumor types at similar stages (Figure 2). These sensitivity issues may also stem from aspects of genetic heterogeneity that we have not yet adequately characterized, and that differ across tumor type (reviewed by Martincorena et al. 38).

Lung cancer represents one oncological setting within which ptDNA-based liquid biopsy is already in widespread use, and where actionable mutations (such as those in the EGFR gene) can be reliably identified in the clinic using liquid biopsy. For example, plasma-based genotyping of non-small cell lung cancers (NSCLCs), via the cobas® EGFR Mutation Test v2, has recently received FDA approval for the diagnosis of specific EGFR mutations (exon 19 deletions, L858R substitution) that can help to determine overall prognosis and eligibility of NSCLC patients for a variety of tyrosine kinase inhibitor (TKI) based therapies 39. This is the first FDA approved ptDNA cancer diagnostic test and foreshadows the potential for ptDNA to survey a tumor's genetic landscape non-invasively in order to guide cancer treatments. This FDA approval has been based on results from a number of recent studies and clinical trials, such as the IGNITE 40,41, ASSESS 40, EURTAC 42, and NCT01203917 trials and their follow up studies 39,43, which showed that informative EGFR mutations could be detected reliably enough with ptDNA to serve as an alternative to tissue based genotyping. Furthermore, the cobas® EGFR Mutation Test v2 can identify up to 42 EGFR mutations, and many of these (like the T790M mutation) represent good candidates for upcoming FDA approval. Recently published retrospective and prospective studies have demonstrated the equivalence in outcomes for patients with both common EGFR activating mutations and the EGFR T790M resistance mutation that received a third-line EGFR TKI, regardless of whether these mutations were identified using DNA extracted from tumor tissue or blood 44,45. While these studies support the efficacy of liquid biopsy based methods in genotyping NSCLCs, the modest diagnostic sensitivity of these approaches (~70%) has led to the continued use of both traditional biopsy and tissue-based genotyping as a diagnostic, whenever clinically feasible, for individuals whose blood based genotyping is negative 39. However, the turn-around time for blood based genotyping can be much faster than traditional approaches, and repeated biopsies over the course of treatment are much more feasible using liquid biopsy 36,39,45,46 (Figure 3).

ptDNA in early stage cancers

Given the limitations of current therapeutics in the treatment of advanced cancers, and the efficacy of surgery in earlier stage cancers when tumors are locally confined, successful use of ptDNA in the context of early stage disease is likely to bring the most clinical benefit. However, since ptDNA levels correlate with tumor stage across tumor types 27,47 (Figure 2), the use of ptDNA in early stage cancers has been challenging due to low ptDNA levels that impede sensitivity in a rate limiting fashion. Nonetheless, in their seminal study of ptDNA across tumor type, Bettegowda et al. were able to detect cancerous disease in slightly more than half of early stage patients 27. Close to 50% of stage I patients had detectable ptDNA levels, while over two-thirds of stage III patients had detectable ptDNA 27. These results suggested that ptDNA assays might serve as a viable monitoring approach in high risk individuals (for example, BRCA gene carriers) who would benefit greatly from early

detection and for whom repeated biopsy or imaging is not feasible (Figures 3&4). Similarly, ptDNA may provide an alternative option for disease detection or mutational profiling in patients for whom traditional biopsy is contraindicated, or for patients whose tumor types tend to release more ptDNA.

In a recent study on the use of ptDNA in early stage breast cancer, Beaver et al. 23 used Sanger sequencing and newer ddPCR approaches to search for mutations at hotspots in the *PIK3CA* gene. In addition to confirming the enhanced capacity of ddPCR to identify mutations compared with Sanger sequencing, they showed that a small number of common cancer mutations were found in almost 50% of early stage breast cancer tumors 23. This demonstrated that ptDNA assays could be developed around common mutation subsets that are profiled simultaneously without the need to first identify mutations in a biopsied tumor specimen. Furthermore, when searching for ptDNA using the identified *PIK3CA* mutations, they reported a specificity of 100%, a sensitivity of 93.3% and an accuracy of 96.7% 23. Lastly, the authors reported the ptDNA mutational status of patients before and after surgery in the context of the histopathology and general presentation of these patients, with half of the patients with detectable ptDNA pre-surgery having detectable ptDNA post-surgery despite showing no other signs of residual disease 23. These data suggest that ptDNA can be used to help stratify patients as more or less likely to benefit from morbid adjuvant treatments that only benefit a minority of patients 23,48.

While many studies have continued to demonstrate the specificity of ptDNA as a broad cancer biomarker, some studies have focused on identifying clinical niches where ptDNA can offer predictive value. In seminal work on the ability of ptDNA to predict relapse in early stage disease, Garcia-Murillas et al. 28 reported that the identification of ptDNA after neoadjuvant treatment and surgery accurately predicted relapse in early stage breast cancer. This prediction could be made accurately with only a single post-surgical plasma sample, and was more sensitive with serially collected plasma samples (depicted in Figure 3), which could signal disease progression a median of 7.9 months before clinical relapse 28. The authors also showed that targeted capture and sequencing of ptDNA could characterize the genetic landscape of minimally residual disease, and that this predicted the mutational profile of the metastatic relapse better than sequencing of the primary tumor sample 28 (Figure 3). In another encouraging study, patients with stage 2 CRC that did not receive adjuvant chemotherapy and had detectable ptDNA levels post-surgery relapsed ~80% of the time by a median follow up of 27 months 49. Contrastingly, similar patients without detectable ptDNA post-surgery relapsed < 10% of the time 49. A similar association between ptDNA levels and recurrence risk was seen in stage 2 CRC patients receiving adjuvant chemotherapy treatment 49. A recent study evaluating the use of liquid biopsy in localized lung cancer identified ptDNA in the first post-treatment blood sample in 94% of patients who recurred, and all stage 1 patients tested had detectable ptDNA 50. This post-treatment ptDNA was identifiable in over 70% of patients a median of 5.2 months before radiographic identification of disease progression and was further used to identify mutation profiles that predict favorable responses to targeted therapies. Scherer et al. could similarly detect ptDNA in the post-treatment plasma of >70% (8/11) of lymphoma patients who ultimately recurred, and ptDNA was not found in any of the 10 patients that were disease-free for 24 months or 54 healthy patients 51. In addition to non-invasively and successfully

profiling the genomic heterogeneity and clonal evolution of these lymphoma tumors, Scherer et al. could predict clinically relevant histologic cancer transformations and progressions using genomic features ascertained exclusively with non-invasive liquid biopsy.

Recent work by Abbosh et al. also utilized ptDNA in early disease contexts to both assess ptDNA levels in early stage patients and determine the clonal and subclonal evolution of tumors during relapse and progression 52. The authors found at least 1 single nucleotide mutation in ~60% (58/96) of patients with early stage NSCLC, as well as significant differences in ptDNA detection rate based on histological subtype that correlated with necrosis and other tumor features associated with ptDNA release. Furthermore, ptDNA was found in 13/14 NSCLC patients that relapsed, whereas only 1/10 patients that did not relapse by at least 688 days had detectable ptDNA. This ptDNA in relapsed patients was found a median of 70 days before radiographic confirmation, with almost 50% of patients demonstrating ptDNA-based lead time of greater than 150 days. Treatment response and resistance was also represented by ptDNA mutation profiling, and subclonal mutation frequency changes predicted which malignant subclones dominated relapse and progression.

Specificity Challenges of ptDNA assays

In spite of the strong body of evidence supporting ptDNA as a highly specific biomarker, several studies have challenged this notion by identifying cancer-associated mutations in the blood plasma of healthy individuals 53,54. While these may represent early mutational events during tumorigenesis, and carriers of these characteristic mutations seem to have elevated cancer risks, significant numbers of patients seem to progress without any manifestation of oncological disease. For example, Fernandez-Cuesta et al. 54 reported that 11.4% of 123 healthy patients were positive for mutations in the canonical tumor suppressor gene *TP53*, and was able to replicate these results in an independent cohort of 102 non-cancerous controls. The finding of purportedly cancer-causing mutations in apparently healthy individuals poses a clinical diagnostic challenge to otherwise highly specific mutation targeted ptDNA assays. This may represent a significant obstacle to the wide spread adoption of ptDNA as a foundational biomarker in initial cancer detection. On the other hand, if the majority of cancer mutations found in the pDNA of healthy individuals represent the DNA of cells that are becoming clinically malignant, then the routine surveillance of pDNA for cancer mutations may help to identify and monitor at-risk individuals in a preventative fashion (Figure 4).

Improving ptDNA detection with *in silico* analytical methods

Due to increased computational capacity, availability of massively parallel sequencing technologies, and high-throughput bioinformatic methods, liquid biopsy approaches are now notably more powerful. For instance, Newman et al. 55,56 recently developed a pivotal approach to liquid biopsy that targets a compilation of recurrently mutated regions in a particular cancer of interest. Once a “selector” has been designed for a particular cancer type, a patient’s tumor DNA is targeted by this selector to capture these recurrently mutated regions. These regions are then deep sequenced to depths of ~10,000x and analyzed for cancerous mutations. This approach allowed for the detection of multiple types of mutations

and was able to identify mutations in >95% of NSCLC tumors. The approach, called Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq), was highly specific for mutant alleles with a frequency of > 0.02%, and was able to identify 100% of stage II-IV disease cases and 50% of stage I disease cases 55. While the identification of 50% of stage I patients may seem suboptimal, these results are significantly better than those achieved by other methods 27,54. In lung cancer in particular, where biopsies are difficult and hazardous to obtain 36,46, resulting in small amounts of genetic material 37, and therapies are of limited efficacy, the ability of CAPP-Seq to utilize very small amounts of tumor DNA to identify disease in early stage patients is very promising (Figure 3). The authors also applied CAPP-Seq to ptDNA to differentiate between radiographically ambiguous results, which could suggest when a radiographic signal was an artifact of radiation treatment or when negative radiographic results were missing minimally residual disease 55. Furthermore, when CAPP-Seq was used in a separate study to analyze ptDNA for mutations underlying acquired resistance in NSCLC, multiple apparent resistance mutations were found in 46% of patients who had previously received first-line targeted inhibitor treatment, and other point mutations and amplifications were differentially associated with different inhibitor-based therapies 57. These results speak to the ubiquity and clinical relevance of tumor heterogeneity and support the use of CAPP-Seq-based liquid biopsy to dynamically identify mutations to guide treatment.

In a follow-up study, Newman et al. 56 were able to further enhance their CAPP-Seq approach with the addition of an *in silico* based integrated digital error suppression (iDES) technique. By recognizing that the background noise they experienced was not random, they utilized datasets to mathematically identify and account for stereotypical errors, significantly increasing the sensitivity, specificity, and accuracy of CAPP-Seq 56. Notably, their computational method alone improved analytical sensitivity by about 3-fold and represents the kinds of improvements than can be made by the appropriate use of *in silico* techniques. When this computational approach was combined with a strategic molecular barcoding enhancement, the two compounded one another and led to an ~15-fold improvement in analytical sensitivity. Ultimately, the iDES CAPP-Seq method enabled the biopsy-free detection of EGFR kinase domain mutations with nearly 100% specificity and 92% sensitivity at the variant level. At the patient level, sensitivity for ptDNA was over 90% and specificity was over 95% 56. While the sample size of early stage patients was small, ptDNA was identified in 3/3 pretreatment plasma samples from early stage patients 56. Furthermore, a more recent study employing iDES CAPP-Seq identified tumorous DNA from pretreatment blood samples in 7/7 stage IB cancers, and were also able to effectively identify and track minimal residual disease 50.

These results achieved by iDES CAPP-Seq are very encouraging and represent sensitivity levels that may facilitate the widespread and reliable use of liquid biopsy for both early stage cancer detection and advanced disease monitoring (Figure 4). Recent work by Phallen et al. 58 builds on elements of this approach, and offers an interesting alternative for ptDNA-based cancer detection using liquid biopsy. By extending the selected regions to include additional genes and somatic hotspot positions, and calibrating this set of captured regions to apply equally well across different cancer types, the authors were able to detect somatic mutations highly specific for cancer in 71%, 59%, 59%, and 68% of early stage colorectal,

breast, lung, and ovarian cancer patients, respectively 58. This approach, termed targeted error correction sequencing, or (TEC-Seq), strategically preps and barcodes pDNA, sequences samples to extreme depths ($> 30,000\times$ coverage), requires mutations to be seen numerous times across identical reads and distinct read pairs, and applies robust filtering criterion to achieve an error rate of $< 3.3 \times 10^{-7}$ false-positive mutation calls per base 58. While such high-depth sequencing is currently prohibitively expensive, and the definition of this error rate is somewhat different than other methods such as iDES CAPP-Seq (false positive rate vs technical error rate), this approach enabled the authors to detect no false positive bases among the 80,930 bases analyzed in error-assessing dilution assays 56,58. Furthermore, and similar to iDES CAPP-Seq, the TECSeq approach aims to reduce false positives by using DNA from matched time point blood cells, and was able to identify genomic alterations indicative of clonal hematopoiesis in 16% of the 44 healthy individuals they assessed. This suggests the possible use of such an approach to monitor healthy individuals for the clonal expansion of cellular populations. While the detection rates of early stage disease by these newer methods are still lower than what would ideally underpin a reliable diagnostic test, they represent forward progress towards the use of pDNA and liquid biopsy for the detection of early stage cancers.

Concluding Remarks

While the findings reviewed thus far demonstrate significant fulfillment of the promise of liquid biopsy to non-invasively and reliably identify cancer patients and guide treatment, the identification of pDNA in the earliest stages of tumor development has been limited. Numerous questions remain regarding how to improve the detection of pDNA in early stage cancers, and whether such detection can ultimately be used for cancer surveillance and diagnosis (see Outstanding Questions). One potential way to enhance the sensitivity of pDNA methods is to identify and employ genomic metrics that vary with tumor progression. While independent mutations require exquisite precision and sensitivity to detect, genome-wide measures are summed across billions of base pairs and may reflect aggregated signal that is undetectable in isolation. When calculated from deeply-sequenced genomes produced by advanced sequencing technologies, such metrics can increase the power to detect otherwise hidden pDNA signals. This is likely why the inclusion of non-canonical mutations (i.e. private mutations) in commonly mutated regions has proven important to the detection of cancerous disease by modern pDNA-based analyses 50,58. While certain variations may require cost-prohibitive ultra-deep sequencing to detect the signal from low-abundance tumor DNA, sequencing costs continue to drop exponentially, and such an approach may ultimately be feasible. An example of one measure that may reflect the onset of cancer is the change over time in the proportion of rare variants found in an individual's plasma DNA. Based on the population genetic concept that rapidly expanding populations exhibit an elevated level of rare variants as they accumulate novel genetic mutations 59,60, one might expect changes in the proportion of rare variants found in pDNA as tumors clonally expand and release their DNA into the blood. Genome-wide measures could potentially also be calibrated around the amount of structural variation found in pDNA or the epigenetic profiles of pDNA.

As the amount of genomic data from tumor samples continues to grow, it should be possible to develop optimal recurrent mutational profiles from all previously analyzed cancers 61,62. As emphasized and demonstrated by Newman et al. and Phallen et al. 55,56,58, changing focus from patient specific mutations to cancer specific assays can be extremely powerful. Mutations identified in this way can be prognostic and can signal that a patient's disease course is likely to resemble that of patients with similar mutational profiles, regardless of tumor tissue type. Furthermore, as outlined in the study by Ciriello et al 61, the increasing characterization of cancer mutational signatures can potentially facilitate the redefinition of tumor classification from a tissue-based system to a mutation-based one. By combining newer deep-sequencing techniques that avoid the need to target a patient's specific mutations with the potential of genome-wide analysis, surveillance of the general population for DNA based cancer signals may become a reality. As outlined in Figure 4, one might imagine a standard blood test that is performed longitudinally, and which focuses on changes in pDNA signal over time that correlate with cancer risk. Liquid biopsy has already shown the potential to significantly impact the treatment of cancer in the clinic, and by leveraging features of pDNA further, clinicians and cancer genomicists can hopefully use liquid biopsy for the noninvasive *de novo* detection of cancer.

Acknowledgements

Feyruz Rassool, Aksinija Kogan, and Kelsey Abernathy provided numerous helpful comments.

Funding

This work was supported by the National Institutes of Health (R01 HL118390 and R01 CA196988 to T.M.A.) (R01 CA154624 to S.S.M.). M.D.K. is supported by NIH T32CA154274. M.D.K. and T.D.O. were supported by funding from the Center for Health Related Informatics and Bioimaging at the University of Maryland School of Medicine and institutional support for the Institute for Genome Sciences and Program in Personalized Genomic Medicine at the University of Maryland School of Medicine.

References

1. Lo YD et al. Presence of fetal DNA in maternal plasma and serum. *The Lancet* 350, 485–487 (1997).
2. Anker P, Mulcahy H, Chen XQ & Stroun M Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. *Cancer and Metastasis Reviews* 18, 65–73 (1999). [PubMed: 10505546]
3. Silva JM et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. *Cancer Res* 59, 3251–6 (1999). [PubMed: 10397273]
4. Haber DA & Velculescu VE Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. *Cancer discovery* 4, 650–661 (2014). [PubMed: 24801577]
5. Wan JC et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. *Nature Reviews Cancer* (2017).
6. Botezatu I et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. *Clin Chem* 46, 1078–84 (2000). [PubMed: 10926886]
7. Su YH et al. Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. *J Mol Diagn* 6, 101–7 (2004). [PubMed: 15096565]
8. Chan KC, Leung SF, Yeung SW, Chan AT & Lo YM Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients. *Clin Cancer Res* 14, 4809–13 (2008). [PubMed: 18676752]

9. Mithani SK et al. Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer. *Clin Cancer Res* 13, 7335–40 (2007). [PubMed: 18094415]
10. Pan W, Gu W, Nagpal S, Gephart MH & Quake SR Brain tumor mutations detected in cerebral spinal fluid. *Clin Chem* 61, 514–22 (2015). [PubMed: 25605683]
11. Wang Y et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. *Proc Natl Acad Sci U S A* 112, 9704–9 (2015). [PubMed: 26195750]
12. Stroun M et al. The origin and mechanism of circulating DNA. *Annals of the New York Academy of Sciences* 906, 161–168 (2000). [PubMed: 10818614]
13. Jahr S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. *Cancer research* 61, 1659–1665 (2001). [PubMed: 11245480]
14. Stroun M, Lyautey J, Lederrey C, Olson-Sand A & Anker P About the possible origin and mechanism of circulating DNA: Apoptosis and active DNA release. *Clinica chimica acta* 313, 139–142 (2001).
15. van der Vaart M & Pretorius PJ The origin of circulating free DNA. *Clinical chemistry* 53, 2215–2215 (2007). [PubMed: 18267930]
16. Punnoose EA et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. *Clinical Cancer Research* 18, 2391–2401 (2012). [PubMed: 22492982]
17. Yoshioka Y et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. *Nature communications* 5(2014).
18. Diaz LA & Bardelli A Liquid biopsies: genotyping circulating tumor DNA. *Journal of Clinical Oncology* 32, 579–586 (2014). [PubMed: 24449238]
19. Heitzer E, Ulz P & Geigl JB Circulating tumor DNA as a liquid biopsy for cancer. *Clinical chemistry* 61, 112–123 (2015). [PubMed: 25388429]
20. Lui YY et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. *Clin Chem* 48, 421–7 (2002). [PubMed: 11861434]
21. Sun K et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. *Proc Natl Acad Sci U S A* 112, E5503–12 (2015). [PubMed: 26392541]
22. Tug S et al. Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. *Exerc Immunol Rev* 21, 164–73 (2015). [PubMed: 25826002]
23. Beaver JA et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. *Clin Cancer Res* 20, 2643–50 (2014). [PubMed: 24504125]
24. Forshew T et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. *Sci Transl Med* 4, 136ra68 (2012).
25. Dawson SJ et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. *N Engl J Med* 368, 1199–209 (2013). [PubMed: 23484797]
26. Murtaza M et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature* 497, 108–12 (2013). [PubMed: 23563269]
27. Bettgowda C et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med* 6, 224ra24 (2014).
28. Garcia-Murillas I et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. *Sci Transl Med* 7, 302ra133 (2015).
29. Diehl F et al. Circulating mutant DNA to assess tumor dynamics. *Nat Med* 14, 985–90 (2008). [PubMed: 18670422]
30. Duffy MJ Clinical uses of tumor markers: a critical review. *Crit Rev Clin Lab Sci* 38, 225–62 (2001). [PubMed: 11451209]
31. Diamandis EP Cancer biomarkers: can we turn recent failures into success? *J Natl Cancer Inst* 102, 1462–7 (2010). [PubMed: 20705936]

32. Diehl F et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. *Proc Natl Acad Sci U S A* 102, 16368–73 (2005). [PubMed: 16258065]
33. Kamat AA et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. *Cancer biology & therapy* 5, 1369–1374 (2006). [PubMed: 16969071]
34. Hindson BJ et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. *Anal Chem* 83, 8604–10 (2011). [PubMed: 22035192]
35. Gevensleben H et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. *Clin Cancer Res* 19, 3276–84 (2013). [PubMed: 23637122]
36. Overman MJ et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? *Journal of Clinical Oncology* 31, 17–22 (2012). [PubMed: 23129736]
37. VanderLaan PA et al. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. *Lung cancer* 84, 39–44 (2014). [PubMed: 24513263]
38. Martincorena I & Campbell PJ Somatic mutation in cancer and normal cells. *Science* 349, 1483–9 (2015). [PubMed: 26404825]
39. Siravegna G, Marsoni S, Siena S & Bardelli A Integrating liquid biopsies into the management of cancer. *Nature reviews Clinical oncology* 14, 531–548 (2017).
40. Bordi P, Del Re M, Danesi R & Tiseo M Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. *Translational lung cancer research* 4, 584 (2015). [PubMed: 26629427]
41. Han B et al. 96O DETERMINING THE PREVALENCE OF EGFR MUTATIONS IN ASIAN AND RUSSIAN PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC) OF ADENOCARCINOMA (ADC) AND NON-ADC HISTOLOGY: IGNITE STUDY. *Annals of Oncology* 26, i29–i30 (2015).
42. Karachaliou N et al. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. *JAMA Oncol* 1, 149–57 (2015). [PubMed: 26181014]
43. Douillard JY et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. *J Thorac Oncol* 9, 1345–53 (2014). [PubMed: 25122430]
44. Oxnard GR et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. *Journal of Clinical Oncology* 34, 3375–3382 (2016). [PubMed: 27354477]
45. Sacher AG et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. *JAMA oncology* 2, 1014–1022 (2016). [PubMed: 27055085]
46. Tomiyama N et al. CT-guided needle biopsy of lung lesions: a survey of severe complication based on 9783 biopsies in Japan. *Eur J Radiol* 59, 60–4 (2006). [PubMed: 16530369]
47. Thierry AR et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. *Nucleic Acids Res* 38, 6159–75 (2010). [PubMed: 20494973]
48. Early Breast Cancer Trialists' Collaborative, G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 365, 1687–717 (2005). [PubMed: 15894097]
49. Tie J et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. *Science Translational Medicine* 8, 346ra92–346ra92 (2016).
50. Chaudhuri AA et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. *Cancer Discov* 7, 1394–1403 (2017). [PubMed: 28899864]
51. Scherer F et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. *Science translational medicine* 8, 364ra155–364ra155 (2016).
52. Abbosh C et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. *Nature* 545, 446 (2017). [PubMed: 28445469]
53. Gormally E et al. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. *Cancer Res* 66, 6871–6 (2006). [PubMed: 16818665]

54. Fernandez-Cuesta L et al. Identification of circulating tumor DNA for the early detection of small-cell lung cancer. *EBioMedicine* 10, 117–123 (2016). [PubMed: 27377626]
55. Newman AM et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. *Nature medicine* 20, 548 (2014).
56. Newman AM et al. Integrated digital error suppression for improved detection of circulating tumor DNA. *Nature biotechnology* (2016).
57. Chabon JJ et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nat Commun* 7, 11815 (2016). [PubMed: 27283993]
58. Phallen J et al. Direct detection of early-stage cancers using circulating tumor DNA. *Sci Transl Med* 9(2017).
59. Hartl DL & Clark AG Principles of population genetics, xv, 652 p. (Sinauer Associates, Sunderland, Mass., 2007).
60. Keinan A & Clark AG Recent explosive human population growth has resulted in an excess of rare genetic variants. *Science* 336, 740–3 (2012). [PubMed: 22582263]
61. Ciriello G et al. Emerging landscape of oncogenic signatures across human cancers. *Nature genetics* 45, 1127 (2013). [PubMed: 24071851]
62. Vogelstein B et al. Cancer genome landscapes. *Science* 339, 1546–58 (2013). [PubMed: 23539594]
63. Leon SA, Shapiro B, Sklaroff DM & Yaros MJ Free DNA in the serum of cancer patients and the effect of therapy. *Cancer Res* 37, 646–50 (1977). [PubMed: 837366]
64. Shapiro B, Chakrabarty M, Cohn EM & Leon SA Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. *Cancer* 51, 2116–2120 (1983). [PubMed: 6188527]
65. Lo YD et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. *Clinical chemistry* 45, 184–188 (1999). [PubMed: 9931039]
66. Vogelstein B & Kinzler KW Digital PCR. *Proc Natl Acad Sci U S A* 96, 9236–41 (1999). [PubMed: 10430926]
67. Wood LD et al. The genomic landscapes of human breast and colorectal cancers. *Science* 318, 1108–13 (2007). [PubMed: 17932254]

Text Box 1. A brief history of cell free tumor DNA.

As early as 1977, Leon et al. 63 recognized the value of cell free tumor DNA in blood, and reported significantly higher levels of DNA in the serum of patients with metastatic disease. Despite limited methods, the signal was strong enough to see a reduction in circulating DNA in response to treatment, a general correlation between DNA reduction and improved clinical condition, and differences in these signals across tumor type. However, the authors struggled to understand the identification of seemingly normal DNA in 50% of cancer patients, and concluded that their test may have limited diagnostic value. This foreshadowed the persistent challenges with achieving adequate diagnostic sensitivity that researchers have faced when using liquid biopsy. Nonetheless, the potential was recognized for better detection methods to improved the use of ptDNA, and this laid important ground work for future studies.

However, despite this potential and subsequent investigation by this group into circulating DNA in cancer patients 64, the next two decades saw a focus on the analysis of circulating tumor cells and non-nucleic acid biomolecules as candidate tumor biomarkers. Little progress was made with circulating DNA until the 1990's, when the successful isolation and analysis of cell-free fetal DNA from the blood of pregnant mothers seemed to reinvigorate the study of circulating tumor DNA 1,65. Improvements in methodology and the optimization of powerful molecular and genetic tools, such as PCR and DNA sequencing, facilitated increases in analytical sensitivity that propelled cell free tumor DNA research forward 2,66. By 1999, digital PCR methods that utilized the dilution and subsequent single molecule amplification of ptDNA were enabling the detection of ~4 mutant alleles among 100 total alleles 66. Within a few years, significant improvements in isolation techniques had enabled researchers to detect tumor DNA molecules as rare as one per 10,000 normal DNA molecules 32. These technical advances, in conjunction with the onset of next generation sequencing and the enormous amount of tumor mutation data it generated, set the stage for the increased clinical application of ptDNA.

Text Box 2. PCR-based Methods for Detecting ptDNA

As next generation sequencing facilitated the identification of characteristic cancer (driving) mutations, it became clear that somatic driver mutations found in tumor samples were highly specific and could be utilized to track disease 29,67. Since DNA arising from solid tumors can be released into the blood (Figure 2), DNA extracted from blood plasma can be interrogated for tumor specific mutations using a variety of technical approaches. The general framework involves the dilution of pDNA to a level where every two aliquots has an average of one DNA molecule (*i.e.* a single genomic fragment) 66. The genomic area flanking identified mutation(s) is then amplified from the isolated pDNA molecules with quantitative PCR based techniques, which allows for the calculation of total DNA concentration per volume of plasma. Probes specific for a patient's identified mutation(s) can then be designed and used to identify mutated DNA among the amplified molecules. These probes are often fluorescent, and facilitate the quantitation of mutant DNA relative to wild type DNA. Finally, this fluorescence signal can be used along with the calculated total DNA to report an estimate of the number of mutant DNA fragments per sample. This approach utilizes *a priori* knowledge of a patient's specific tumor mutations to evaluate pDNA in a personalized way. Applying this approach to the plasma of patients collected after tumor resection, or to the plasma of patients receiving chemical therapies, can enable the assessment of treatment-associated changes in ptDNA with potentially predictive value. However, since ptDNA molecules derived from cancers are often exceedingly rare compared with normal circulating DNA molecules 32, analytical sensitivity thresholds can be a limiting factor. Knowing this, many investigators have focused on accurately quantifying ptDNA in advanced stage cancers that are associated with elevated amounts of pDNA.

- Liquid biopsy approaches are becoming increasingly facile at detecting and monitoring signatures of oncological disease in a non-invasive fashion.
- Recent technological developments have greatly increased the sensitivity with which rare cancer specific mutations can be identified from the blood.
- Mutation targeted approaches that probe for an individual's specific mutations have the highest sensitivity but also require prior biopsy and/or personalized assay development.
- Mutation agnostic approaches, particularly those reliant on extreme-depth massively parallel sequencing, allow for the identification of mutations common to subsets of cancers, and represent the best opportunity to actualize the promise of liquid biopsy.

Outstanding questions:

- ☐ Given the low levels of ptDNA during initial cancer development, and the limited analytical sensitivity of current approaches, how can the detection of ptDNA in patients with early stage cancers be improved?
- ☐ How can we use genome-wide measures that are summed across billions of base pairs, like rare variation levels or shifts in copy number variation, to aggregate signal that is undetectable in isolation and indicate the development of cancers?
- ☐ Can we develop optimal recurrent mutational profiles from previously analyzed cancers to underpin cancer targeting assays that do not need *a priori* knowledge of a patient's specific mutations?
- ☐ Will ptDNA-based liquid biopsy enable surveillance of the general population for DNA mutations that signal the development of cancerous disease?

Figure 1|. Acronyms describing free DNA in body fluids. Acronyms and terms are presented in (A) and representative locations of frequently analyzed body fluids are illustrated in (B). Green hexagons represent tumors.

Figure 2]. Clonal expansion of a solid tumor and DNA release into the blood.

As a tumor develops and clonally expands its cell number, fragments of tumor DNA (ptDNA; green) begin to enter the blood stream to join the normal DNA (white) that exists at baseline in the blood of healthy individuals. Together, the ptDNA and normal DNA make up the total DNA found in the plasma (pDNA). As the tumor increases in size, additional copies of tumor-derived DNA enter the blood stream, although this correlation appears to differ across tumor type and stage 27. These tumor DNA fragments can be identified by canonical mutations (gold stars) that underpin oncogenic features. Note- tumor size/cell number is representative of overall trends in tumor progression as opposed to the expected number of cells in a tumor when tumor-derived DNA is first being appreciably released.

Figure 3|. Traditional biopsy vs liquid biopsy.

Tumor biopsies are an essential component of cancer care. Traditional tumor biopsies frequently require invasive procedures, and can be limited by the patient's poor health, the location of the tumor, tumor heterogeneity, and insufficient tumor tissue. Compared with traditional biopsy, liquid biopsy offers a non-invasive option for detecting and monitoring oncological disease. By extracting tumor DNA from the blood plasma, tissue injury and complications associated with traditional biopsy are eliminated. A more complete survey of the heterogeneous genomic landscape of a tumor may also be obtained, and the process is easily repeatable over time in order to perform longitudinal and replicative analysis. As a result of the short half life of tumor DNA in the blood (half-life on the scale of minutes to hours), liquid biopsy is a much more dynamic approach, and can facilitate the nearly real-time monitoring of disease dynamics in response to surgical intervention and treatment. Liquid biopsy also avoids the issues of insufficient genomic material and pathogenic disruption of the local tumor environment that are associated with traditional biopsy. Finally, while sensitivity thresholds are not high enough yet to allow for the use of liquid biopsy in the *de novo* detection of cancer, the ease of access to the blood and the nearly non-existent morbidity of this approach suggest that routine cancer surveillance using liquid biopsy is possible.

Figure 4|. Hypothetical longitudinal patient surveillance and detection of early cancer biomarkers using liquid biopsies

A theoretical approach to a liquid biopsy-based cancer detection blood test is depicted. From birth, and at established intervals, an individual would receive a blood test to evaluate their pDNA for features representative of cancer. Those whose tests were positive, based on a compendium of cancer mutation information and associations, could be referred for more in depth clinical evaluation and monitoring. This would hopefully increase the likelihood of identifying potential cancers at their earliest and most treatable stages, and might help to significantly reduce cancer mortality rates. Individuals with cancer who achieve remission might similarly be monitored by liquid biopsy-based approaches, and might eventually re-enter the standard surveillance paradigm.